Here you can see and modify the cookie settings of various tools used on and related subdomains.

Save settings
Advantage Austria Show navigation
We think you are in the USAGo to this country pageChange country

Kazakhstan gets an economic injection

Takeda/Nycomed Austria is Austria’s largest exporter of pharmaceuticals to Kazakhstan. Annually, the company turns over some 40 million Euros in the region, making it the third largest pharmaceutical supplier on the local market.

The Takeda group is the world’s twelfth largest pharmaceutical company. Following its acquisition of the Nycomed Group, Takeda is to significantly expand its Linz facility, doubling production of biological actives over the coming years.

The company is present in over 70 countries, with a particular focus on Asia, North America, and Europe, as well as high growth, emerging markets like Latin America, Russia and the wider CIS, and China.

Kazakhstan’s increasing prosperity is reflected in its growing health sector. It is a market that remains heavily dependent on imports in almost all product areas, and the ever-rising demand for quality health products and facilities means this is unlikely to change any time soon.

Takeda/Nycomed’s ability to apply its expertise to supporting the Kazakhstani market is proving enormously beneficial for the company. The key treatment areas in which it has established itself are metabolic disorders, gastroenterology, oncology, cardiovascular health, and inflammatory diseases.

The company’s success helps to explain why a typical breakdown of Austrian exports does not hold true for Central Asia, where “chemical products” (overwhelmingly medical and pharmaceutical supplies) constitute a significantly more valuable proportion of Austrian exports than either “machinery and automotive products” or “manufactured goods”.